Igen Biolab Group
  • Home
  • About Us
  • Technology
  • Pipeline
  • Press
    • News
    • Press Releases
    • Events
    • Publications
  • Contact
  • English
    • Español
Select Page
A pilot study of the sequencing of the intestinal microbiota for colon cancer

A pilot study of the sequencing of the intestinal microbiota for colon cancer

by Igen BioLab Group | Jul 10, 2020 | News, Publications

The intestinal microbiota, composed by the microorganisms that live in our intestines, can give us information about our health, since its composition may depend on factors such as the diet, the lifestyle or our pathologies. Moreover, knowing what specific bacteria...
Re-evaluating the relationship between missing heritability and the microbiome

Re-evaluating the relationship between missing heritability and the microbiome

by Igen BioLab Group | Jun 18, 2020 | News, Publications

Human genome-wide association studies (GWASs) have recurrently estimated lower heritability estimates than familial studies. Many explanations have been suggested to explain these lower estimates, including that a substantial proportion of genetic variation and...
Genome and sequence determinants governing the expression of horizontally acquired DNA in bacteria

Genome and sequence determinants governing the expression of horizontally acquired DNA in bacteria

by Igen BioLab Group | Jun 15, 2020 | News, Publications

While horizontal gene transfer is prevalent across the biosphere, the regulatory features that enable expression and functionalization of foreign DNA remain poorly understood. Here, we combine high-throughput promoter activity measurements and large-scale genomic...

Recent Posts

  • The role of gut microbiota in cancer treatment: friend or foe?
  • Symbiotic polyamine metabolism regulates epithelial proliferation and macrophage differentiation in the colon
  • Inter-microbial relations shape the preterm gut
  • The Microbiome and Cancer: Creating Friendly Neighborhoods and Removing the Foes Within
  • Gut Microbiota Condition the Therapeutic Efficacy of Trastuzumab in HER2-Positive Breast Cancer
  • Aviso legal
  • Política de Privacidad
  • Política de cookies
  • Facebook
  • Twitter
  • Google
  • Instagram
  • RSS
Design by loComunicas
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Cookie settingsACCEPT
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled

Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.

Non-necessary

Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.

SAVE & ACCEPT